Riociguat: A Review of Its Use in Patients with Chronic Thromboembolic Pulmonary Hypertension or Pulmonary Arterial Hypertension

@article{GarnockJones2014RiociguatAR,
  title={Riociguat: A Review of Its Use in Patients with Chronic Thromboembolic Pulmonary Hypertension or Pulmonary Arterial Hypertension},
  author={Karly P. Garnock-Jones},
  journal={Drugs},
  year={2014},
  volume={74},
  pages={2065-2078}
}
Riociguat (Adempas®), a soluble guanylate cyclase stimulator, is a new, first-in-class drug approved for the treatment of patients with chronic thromboembolic pulmonary hypertension (CTEPH) [inoperable or persistent/recurrent following surgery] or pulmonary arterial hypertension (PAH). It has been designated an orphan medicine by the European Medicines… CONTINUE READING